Comparison of Safety and Diagnostic Efficacy of Iohexol 240 mgI/mL, Iopamidol 250 mgI/mL, and Iodixanol 270 mgI/mL in Cerebral Angiography: A Prospective, Multicenter Study
Open Access
- 1 July 2024
- journal article
- research article
- Published by Korean Society of Interventional Neuroradiology in Neurointervention
- Vol. 19 (2) , 82-91
Abstract
Purpose: This multicenter prospective study aimed to evaluate the quality and diagnostic effectiveness of cerebral angiography images obtained using low-concentration iodinated contrast agents (iohexol 240 mgI/mL, iopamidol 250 mgI/mL, and iodixanol 270 mgI/mL) and to assess the safety thereof. The study addresses the need for safer contrast agent alternatives without compromising the diagnostic quality of identifying cerebrovascular disease.Materials and Methods: Conducted in 5 medical centers in South Korea, we enrolled patients aged 19 years or older who were referred for diagnostic cerebral angiography under non-emergency conditions, excluding those with specific health conditions and sensitivities. The study design included a prospective, observational approach with a 1-way analysis of variance (ANOVA) for sample size calculation, aiming for a total sample of 231 participants for adequate power. Image quality was evaluated using a 4-level scale by 2 independent, blinded radiologists, and adverse reactions were monitored both immediately and up to 7 days post-procedure. Statistical analysis involved 1-way ANOVA and Kruskal–Wallis tests to assess the image quality and safety profiles of the contrast agents.Results: Among 266 patients screened, 243 were included in the final analysis. The evaluation revealed no statistically significant differences in image quality among the 3 types of low-concentration contrast agents. Adverse events were observed in 28.8% of patients, with 27.2% experiencing acute reactions, primarily mild reactions, and 3.3% experiencing delayed reactions. The overall safety profile showed no significant changes in vital signs or electrocardiogram readings before and after contrast agent injection.Conclusion: Using low-concentration iodinated contrast agents for cerebral angiography provides image quality comparable to that of conventional high-concentration agents, with no significant increase in adverse events, suggesting a safer alternative for patients.Keywords
Funding Information
- Central Medical Service (CMS) Co., Ltd.
This publication has 25 references indexed in Scilit:
- Safety and tolerability of iobitridol in cerebral angiography: a prospective, multicenter studyActa Radiologica, 2019
- Feasibility of ultra-low radiation dose digital subtraction angiography: Preliminary study in a simplified cerebral angiography phantomInterventional Neuroradiology, 2019
- Image Quality of Low-Dose Cerebral Angiography and Effectiveness of Clinical Implementation on Diagnostic and Neurointerventional Procedures for Intracranial AneurysmsAmerican Journal of Neuroradiology, 2019
- Comparison of patient comfort between iodixanol and iopamidol in contrast-enhanced computed tomography of the abdomen and pelvis: a randomized trialActa Radiologica, 2014
- Current Utility of Diagnostic Catheter Cerebral AngiographyJournal of Stroke and Cerebrovascular Diseases, 2014
- Risk factors for adverse reactions from contrast agents for computed tomographyBMC Medical Informatics and Decision Making, 2013
- Renal safety in pediatric imaging: randomized, double-blind phase IV clinical trial of iobitridol 300 versus iodixanol 270 in multidetector CTPediatric Radiology, 2011
- Are there any differences in acute adverse reactions among five low-osmolar non-ionic iodinated contrast media?European Radiology, 2009
- Adverse reactions to intravenous iodinated contrast media: a primer for radiologistsEmergency Radiology, 2006
- SAFETY OF CONTRAST-MEDIA IN CEREBRAL-ANGIOGRAPHY - IOPAMIDOL VS METHYLGLUCAMINE LOTHALAMATE1984